TY - JOUR
T1 - Update 2018
T2 - 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer
AU - Sanli, Yasemin
AU - Zukotynski, Katherine
AU - Mittra, Erik
AU - Chen, Delphine L.
AU - Nadel, Helen
AU - Niederkohr, Ryan D.
AU - Subramaniam, Rathan
PY - 2018/12/1
Y1 - 2018/12/1
N2 - There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of 18F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy 18F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.
AB - There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of 18F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy 18F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.
KW - head and neck cancer
KW - PET/CT
KW - PET/MR
UR - http://www.scopus.com/inward/record.url?scp=85056267269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056267269&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000002247
DO - 10.1097/RLU.0000000000002247
M3 - Article
C2 - 30394934
AN - SCOPUS:85056267269
SN - 0363-9762
VL - 43
SP - E439-E452
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 12
ER -